Login Register Cart 0
Review Article

口服 Semaglutide 治疗 2 型 DM：临床状态和比较分析

卷 23, 期 3, 2022

发表于: 24 November, 2021

页: [311 - 327] 页: 17

弟呕挨: 10.2174/1389450122666210901125420

价格: $65

摘要

背景：在肠促胰岛素系统中，胰高血糖素样肽-1 (GLP-1) 是一种抑制胰高血糖素释放并调节葡萄糖依赖性胰岛素分泌的激素。在 2 型糖尿病中，使用 GLP-1 激动剂纠正受损的肠促胰岛素系统是一种明确的治疗策略。目的：这篇综述文章旨在讨论索马鲁肽与二线抗糖尿病药物的作用机制、关键调控事件、血糖控制的临床试验以及比较分析。 描述：Semaglutide 是一种胰高血糖素样肽 1 (GLP-1) 受体激动剂，可增强糖尿病患者的血糖控制。 2019 年，美国食品和药物管理局批准了第一种口服 GLP-1 受体激动剂索马鲁肽，以每日一次的片剂形式给药。此外，最近的研究强调了索马鲁肽改善体重减轻的肥胖患者血糖控制的能力。尽管如此，在临床实践中，在 2 型 DM 治疗范式中，口服索马鲁肽的影响仍未确定。这篇综述文章讨论了有关血糖控制的作用机制、药效学、关键调节事件和临床试验。 结论：该评价通过强调其益处和不良事件，突出了索马鲁肽与现有二线药物治疗 2 型糖尿病的比较分析。

关键词: 口服 Semaglutide，GLP-1 受体激动剂，作用机制，2 型糖尿病，血糖控制，肠促胰岛素系统

« Previous
图形摘要

[1]
Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2014; 2(1): 56-64.
[http://dx.doi.org/10.1016/S2213-8587(13)70112-8] [PMID: 24622669]
[2]
Zimmet PZ, Alberti KGMM. Epidemiology of diabetes-status of a pandemic and issues around metabolic surgery. Diabetes Care 2016; 39(6): 878-83.
[http://dx.doi.org/10.2337/dc16-0273] [PMID: 27222545]
[3]
Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014; 383(9922): 1084-94.
[http://dx.doi.org/10.1016/S0140-6736(13)62219-9] [PMID: 24315621]
[4]
Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (United Kingdom) 2019; 47: 22-7.
[5]
Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon) 2014; 42: 698-702.
[http://dx.doi.org/10.1016/j.mpmed.2014.09.007] [PMID: 25568613]
[6]
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
[7]
Meuleneire F. Management of diabetic foot ulcers using dressings with safetac®: A review of case studie. Wounds 2008; 4(4): 16-30.
[8]
American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2015; 38: S8-S16.
[9]
Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290(3): E550-9.
[http://dx.doi.org/10.1152/ajpendo.00326.2004] [PMID: 16219666]
[10]
Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral semaglutide: A review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol Ther 2020; 22(1): 10-8.
[http://dx.doi.org/10.1089/dia.2019.0185] [PMID: 31436480]
[11]
Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 2015; 55(5): 497-504.
[http://dx.doi.org/10.1002/jcph.443] [PMID: 25475122]
[12]
Gotfredsen CF, Mølck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes 2014; 63(7): 2486-97.
[http://dx.doi.org/10.2337/db13-1087] [PMID: 24608440]
[13]
Maguire A, Douglas I, Smeeth L, Thompson M. Pharmacoepidemiol Drug Saf 2007; 16: 228-8.
[14]
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140-9.
[http://dx.doi.org/10.2337/dc14-2441] [PMID: 25538310]
[15]
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019; 10: 155.
[http://dx.doi.org/10.3389/fendo.2019.00155] [PMID: 31031702]
[16]
Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43(9): 1664-9.
[http://dx.doi.org/10.1021/jm9909645] [PMID: 10794683]
[17]
Hedrington MS, Davis SN. Oral semaglutide for the treatment of type 2 diabetes. Expert Opin Pharmacother 2019; 20(2): 133-41.
[http://dx.doi.org/10.1080/14656566.2018.1552258] [PMID: 30499733]
[18]
FDA. Highlights of prescribing information of ozempic; 2020; pp. 1-51. label (fda.gov)
[19]
FDA. Highlights of Prescribing Information of Rybelsus; 2019. label (fda.gov)
[20]
Nordisk Novo A/S. Victoza (Liraglutide) Full Prescription Information. FDA Packag. Inser. In: 2010; pp. 1-23. Victoza (liraglutide [rDNA origin] injection (fda.gov)
[21]
European Medicines Agency (EMA). Trulicity dulaglutide EPAR 2015; 44: 1-167. TRULICITY, INN-dulaglutide (europa.eu)
[22]
FDA. Cent drug eval res appl number 125469Orig1s000 labeling 2014.
[23]
FDA TANZEUM (albiglutide) for injection, for subcutaneous use Initial U.S. Approval: 2014. FDA-Approved Drugs - Drugs@FDA 2014.
[24]
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87(4): 1409-39.
[http://dx.doi.org/10.1152/physrev.00034.2006] [PMID: 17928588]
[25]
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132(6): 2131-57.
[http://dx.doi.org/10.1053/j.gastro.2007.03.054] [PMID: 17498508]
[26]
Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009; 587(1): 27-32.
[http://dx.doi.org/10.1113/jphysiol.2008.164012] [PMID: 19001044]
[27]
Thurmond DC. Insulin-regulated glucagon-like peptide-1 release from L cells: actin’ out. Endocrinology 2009; 150(12): 5202-4.
[http://dx.doi.org/10.1210/en.2009-1178] [PMID: 19933397]
[28]
Tian L, Jin T. The incretin hormone GLP-1 and mechanisms underlying its secretion. J Diabetes 2016; 8(6): 753-65.
[http://dx.doi.org/10.1111/1753-0407.12439] [PMID: 27287542]
[29]
From GP-S, Gribble FM, Williams L, Simpson AK, Reimann F. Diabetes 2003; 52: 1147.
[http://dx.doi.org/10.2337/diabetes.52.5.1147] [PMID: 12716745]
[30]
Gorboulev V, Schürmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012; 61(1): 187-96.
[http://dx.doi.org/10.2337/db11-1029] [PMID: 22124465]
[31]
Reimann F, Gribble FM. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002; 51(9): 2757-63.1: 2757-63.
[http://dx.doi.org/10.2337/diabetes.51.9.2757] [PMID: 12196469]
[32]
Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 2008; 8(6): 532-9.
[http://dx.doi.org/10.1016/j.cmet.2008.11.002] [PMID: 19041768]
[33]
Ahead P A. City 2010; 1-31.
[34]
Bortolato A, Doré AS, Hollenstein K, Tehan BG, Mason JS, Marshall FH. Structure of Class B GPCRs: new horizons for drug discovery. Br J Pharmacol 2014; 171(13): 3132-45.
[http://dx.doi.org/10.1111/bph.12689] [PMID: 24628305]
[35]
Mayo KE, Miller LJ, Bataille D, et al. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55(1): 167-94.
[http://dx.doi.org/10.1124/pr.55.1.6] [PMID: 12615957]
[36]
Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113(3): 546-93.
[http://dx.doi.org/10.1016/j.pharmthera.2006.11.007] [PMID: 17306374]
[37]
Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: Current advancements & challenges. Biomed Pharmacother 2018; 108: 952-62.
[http://dx.doi.org/10.1016/j.biopha.2018.08.088] [PMID: 30372907]
[38]
Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden DJ. Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C 10). Pharmaceutics 2019; 11(2): 78.
[http://dx.doi.org/10.3390/pharmaceutics11020078]
[39]
Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018; 10(467): eaar7047.
[http://dx.doi.org/10.1126/scitranslmed.aar7047] [PMID: 30429357]
[40]
Hess S, Rotshild V, Hoffman A. Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. Eur J Pharm Sci 2005; 25(2-3): 307-12.
[http://dx.doi.org/10.1016/j.ejps.2005.03.003] [PMID: 15911227]
[41]
Baekdal TA, Thomsen M, Kupčová V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol 2018; 58(10): 1314-23.
[http://dx.doi.org/10.1002/jcph.1131] [PMID: 29693715]
[42]
Anderson SL, Beutel TR, Trujillo JM. Oral semaglutide in type 2 diabetes. J Diabetes Complications 2020; 34(4): 107520.
[http://dx.doi.org/10.1016/j.jdiacomp.2019.107520] [PMID: 31952996]
[43]
Bækdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of oral semaglutide on the pharmacokinetics of Lisinopril, Warfarin, Digoxin, and metformin in healthy subjects. Clin Pharmacokinet 2019; 58(9): 1193-203.
[http://dx.doi.org/10.1007/s40262-019-00756-2] [PMID: 30945118]
[44]
European Medicines Agency (EMA). Prod Inf
[45]
FDA. Semaglutide Injection. Product Quality Review. Cent DRUG Eval Res Appl NUMBER 209637Orig1s000 Prod Qual Rev 2017. 209637Orig1s000ChemR.pdf fda.gov
[46]
FDA. Semaglutide: clinical pharmacology and biopharmaceutics review(s); 2016. 209637Orig1s000ClinPharmR.pdf fda.gov
[47]
FDA. Highlights of prescribing information 2017. OZEMPIC (semaglutide) injection, for subcutaneous use fda.gov
[48]
European medicines agency (EMA). EPAR-Ozempic (Semaglutide). Summary of product characteristics. 1-73. Ozempic, INN-semaglutide europa.eu
[49]
Pharmaceuticals and Medical Devices Agency (PMDA) Japan. New drug approved in FY 2017. 000232769.pdf pmda.go.jp
[50]
Inc., N. N. C. Ozempic (semaglutide injection) product monograph 2018.
[51]
Canada H. Rybelsus®(semaglutide tablets) Product Monograph. Product information canada.ca
[52]
Therapeutic good adinistration, department of health, australian government. OZEMPIC 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen. TGA Search funnelback.com
[53]
Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (sustain 3): A 56-week, open-label, randomized clinical trial. Diabetes Care 2018; 41(2): 258-66.
[http://dx.doi.org/10.2337/dc17-0417] [PMID: 29246950]
[54]
Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (sustain 5): A randomized, controlled trial. J Clin Endocrinol Metab 2018; 103(6): 2291-301.
[http://dx.doi.org/10.1210/jc.2018-00070] [PMID: 29688502]
[55]
Rosenstock J, Allison D, Birkenfeld AL, et al. JAMA - J Am Med Assoc 2019; 321: 1466-80.
[http://dx.doi.org/10.1001/jama.2019.2942] [PMID: 30903796]
[56]
Coronavirus disease 2019 (COVID-19) Situation Report – 88. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
[57]
FDA. Center for drug evaluation and research. application number: 213051orig1s000 Clinical Review(S). Review (fda.gov)
[58]
EMA. Product information of rybelsus epar product information. Rybelsus, INN-semaglutide (europa.eu)
[59]
Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289(1): 76-9.
[http://dx.doi.org/10.1001/jama.289.1.76] [PMID: 12503980]
[60]
Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition 2010; 26(3): 243-9.
[http://dx.doi.org/10.1016/j.nut.2009.07.008] [PMID: 20152707]
[61]
Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012; 62(5-6): 1916-27.
[http://dx.doi.org/10.1016/j.neuropharm.2011.12.022] [PMID: 22227019]
[62]
Monami M, Dicembrini I, Marchionni N, Rotella C M, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012; 2012: 672658.
[63]
Heppner KM, Kirigiti M, Secher A, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2015; 156(1): 255-67.
[http://dx.doi.org/10.1210/en.2014-1675] [PMID: 25380238]
[64]
Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 2010; 100(5): 503-10.
[http://dx.doi.org/10.1016/j.physbeh.2010.02.029] [PMID: 20226203]
[65]
Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol 2016; 310(10): R885-95.
[http://dx.doi.org/10.1152/ajpregu.00520.2015] [PMID: 27030669]
[66]
Bliss ES, Whiteside E. The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Front Physiol 2018; 9: 900.
[67]
Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017; 19(9): 1242-51.
[http://dx.doi.org/10.1111/dom.12932] [PMID: 28266779]
[68]
Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014; 74(15): 1769-84.
[http://dx.doi.org/10.1007/s40265-014-0298-1] [PMID: 25274537]
[69]
Frampton JE. Empagliflozin: A review in type 2 diabetes. Drugs 2018; 78(10): 1037-48.
[http://dx.doi.org/10.1007/s40265-018-0937-z] [PMID: 29946963]
[70]
Al Jobori H, Daniele G, Adams J, et al. Empagliflozin treatment is associated with improved β-cell function in type 2 diabetes mellitus. J Clin Endocrinol Metab 2018; 103(4): 1402-7.
[http://dx.doi.org/10.1210/jc.2017-01838] [PMID: 29342295]
[71]
Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16(5): 457-66.
[http://dx.doi.org/10.1111/dom.12244] [PMID: 24320621]
[72]
Merovci A, Solis-Herrera C, Daniele G, et al. J Clin Invest 2014; 124: 2287.
[http://dx.doi.org/10.1172/JCI76184]
[73]
Röhrborn D, Wronkowitz N, Eckel J. Front Immunol 2015; 6: 1-20.
[http://dx.doi.org/10.3389/fimmu.2015.00386] [PMID: 25657648]
[74]
Gupta V. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab 2013; 17(3): 413-21.
[http://dx.doi.org/10.4103/2230-8210.111625] [PMID: 23869296]
[75]
Reutens AT, Shaw JE. Incretin mimetics and enhancers: clinical applications. Aust Prescr 2008; 31: 104-8.
[http://dx.doi.org/10.18773/austprescr.2008.059]
[76]
DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13(11): 1145-54.
[http://dx.doi.org/10.1089/dia.2011.0050] [PMID: 21751887]
[77]
Atkinson MA. Chapter 32 – type 1 diabetes mellitus. Thirteenth. Elsevier Inc. 2016.
[78]
Pro.medicin.dk Lantus®. ProMedicinDk 2015; 6
[79]
Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010; 6: 541-8.
[http://dx.doi.org/10.2147/VHRM.S10952] [PMID: 20730070]
[80]
Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019; 79(3): 219-30.
[http://dx.doi.org/10.1007/s40265-019-1057-0] [PMID: 30701480]
[81]
Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med 2017; 129(7): 686-97.
[http://dx.doi.org/10.1080/00325481.2017.1342509] [PMID: 28657399]
[82]
Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016; 65(5): 1190-5.
[http://dx.doi.org/10.2337/db15-1356] [PMID: 26861783]
[83]
Tsai AG, Bessesen DH. Obesity. Ann Intern Med 2019; 170(5): ITC33-48.
[http://dx.doi.org/10.7326/AITC201903050] [PMID: 30831593]
[84]
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016; 18(8): 783-94.
[http://dx.doi.org/10.1111/dom.12670] [PMID: 27059700]
[85]
Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide versus Empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The pioneer 2 trial. Diabetes Care 2019; 42(12): 2272-81.
[http://dx.doi.org/10.2337/dc19-0883] [PMID: 31530666]
[86]
Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019; 394(10192): 39-50.
[http://dx.doi.org/10.1016/S0140-6736(19)31271-1] [PMID: 31186120]
[87]
Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 2019; 42(9): 1724-32.
[http://dx.doi.org/10.2337/dc19-0749] [PMID: 31186300]
[88]
Sorli C, Harashima Sichi, Tsoukas G M, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet diabetes endocrinol 2017; 5: 251-60.
[http://dx.doi.org/10.1016/S2213-8587(17)30013-X] [PMID: 28110911]
[89]
Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019; 7: 515-27.
[http://dx.doi.org/10.1016/S2213-8587(19)30192-5] [PMID: 31189517]
[90]
Einarson TR, Acs A, Ludwig C, Panton UH. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes. Cardiovasc Diabetol 2018; 17: 1-19.
[http://dx.doi.org/10.1186/s12933-018-0728-6] [PMID: 29301528]
[91]
European Medicines Agency (EMA) EPAR. Trulicity (Dulaglutide) public assessment report. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity
[92]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834-44.
[http://dx.doi.org/10.1056/NEJMoa1607141] [PMID: 27633186]
[93]
Pearson S, Kietsiriroje N, Ajjan RA. Diabetes. Diabetes Metab Syndr Obes 2019; 12: 2515-29.
[http://dx.doi.org/10.2147/DMSO.S229802] [PMID: 31819577]
[94]
Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381(9): 841-51.
[http://dx.doi.org/10.1056/NEJMoa1901118] [PMID: 31185157]
[95]
Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev 2019; 20(6): 805-15.
[http://dx.doi.org/10.1111/obr.12839] [PMID: 30768766]
[96]
Xiao Y, Sun L. Semaglutide in weight management. Lancet 2019; 394(10205): 1226.
[http://dx.doi.org/10.1016/S0140-6736(18)33195-7] [PMID: 31591979]
[97]
Carreras-Torres R, Johansson M, Haycock PC, et al. Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. BMJ 2018; 361.
[http://dx.doi.org/10.1136/bmj.k1767]
[98]
Nedeltcheva AV, Kilkus JM, Imperial J, Schoeller DA, Penev PD. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med 2010; 153(7): 435-41.
[http://dx.doi.org/10.7326/0003-4819-153-7-201010050-00006] [PMID: 20921542]
[99]
Wilding JPH. Semaglutide in weight management - author’s reply. Lancet 2019; 394(10205): 1226-7.
[http://dx.doi.org/10.1016/S0140-6736(19)31904-X] [PMID: 31591978]
[100]
O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392(10148): 637-49.
[http://dx.doi.org/10.1016/S0140-6736(18)31773-2] [PMID: 30122305]
[101]
Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the step trials 1 to 5. Obesity (Silver Spring) 2020; 28(6): 1050-61.
[http://dx.doi.org/10.1002/oby.22794] [PMID: 32441473]
[102]
Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacology 2018; 136(Pt B): 251-9.
[http://dx.doi.org/10.1016/j.neuropharm.2018.01.040] [PMID: 29402504]
[103]
Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 2006; 9(1): 13-33.
[http://dx.doi.org/10.3233/JAD-2006-9102] [PMID: 16627931]
[104]
Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010; 31(2): 224-43.
[http://dx.doi.org/10.1016/j.neurobiolaging.2008.04.002] [PMID: 18479783]
[105]
Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122(4): 1316-38.
[http://dx.doi.org/10.1172/JCI59903] [PMID: 22476197]
[106]
Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
[http://dx.doi.org/10.3233/JAD-2005-7107] [PMID: 15750215]
[107]
Morris JK, Bomhoff GL, Gorres BK, et al. Insulin resistance impairs nigrostriatal dopamine function. Exp Neurol 2011; 231(1): 171-80.
[http://dx.doi.org/10.1016/j.expneurol.2011.06.005] [PMID: 21703262]
[108]
Morris JK, Zhang H, Gupte AA, Bomhoff GL, Stanford JA, Geiger PC. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson’s disease. Brain Res 2008; 1240: 185-95.
[http://dx.doi.org/10.1016/j.brainres.2008.08.089] [PMID: 18805403]
[109]
Pellecchia MT, Santangelo G, Picillo M, et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson’s disease. Eur J Neurol 2014; 21(5): 802-7.
[http://dx.doi.org/10.1111/ene.12137] [PMID: 23551560]
[110]
Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 2014; 20(2): 212-6.
[http://dx.doi.org/10.1016/j.parkreldis.2013.11.005] [PMID: 24280021]
[111]
Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson’s disease, insulin resistance and novel agents of neuroprotection. Brain 2013; 136(Pt 2): 374-84.
[http://dx.doi.org/10.1093/brain/aws009] [PMID: 22344583]
[112]
Daniels D, Mietlicki-Baase EG. Glucagon-like peptide 1 in the brain: where is it coming from, where is it going? Diabetes 2019; 68(1): 15-7.
[http://dx.doi.org/10.2337/dbi18-0045] [PMID: 30573675]
[113]
Zhang L, Zhang L, Li L, Hölscher C. Semaglutide is neuroprotective and reduces α-synuclein levels in the chronic MPTP mouse model of Parkinson’s disease. J Parkinsons Dis 2019; 9(1): 157-71.
[http://dx.doi.org/10.3233/JPD-181503] [PMID: 30741689]
[114]
Femminella GD, Frangou E, Love SB, et al. The bowel preparation for magnetic resonance enterography in patients with Crohn's disease: study protocol for a randomized controlled trial. Trials 2019; 20: 1-10.
[http://dx.doi.org/10.1186/s13063-019-3259-x] [PMID: 30606236]
[115]
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27(4): 740-56.
[http://dx.doi.org/10.1016/j.cmet.2018.03.001] [PMID: 29617641]
[116]
Barbato GM, Cadamuro M, Fabris L. Incretin-based treatment in type 2 diabetes mellitus and risk of cholangiocarcinoma: Is it only adverse drug effect? Clin Res Hepatol Gastroenterol 2019; 43(3): 232-5.
[http://dx.doi.org/10.1016/j.clinre.2019.01.009] [PMID: 30833185]
[117]
Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3(3): 153-65.
[http://dx.doi.org/10.1016/j.cmet.2006.01.004] [PMID: 16517403]
[118]
Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33(2): 187-215.
[http://dx.doi.org/10.1210/er.2011-1052] [PMID: 22323472]
[119]
Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473-86.
[http://dx.doi.org/10.1210/en.2009-1272] [PMID: 20203154]
[120]
Liu Y, Zhang X, Chai S, Zhao X, Ji L. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: A meta-analysis. J Diabetes Res 2019; 2019: 1534365.
[http://dx.doi.org/10.1155/2019/1534365] [PMID: 31396537]

Rights & Permissions Print Cite
Article Metrics
58
1
© 2025 Bentham Science Publishers | Privacy Policy